Advances in human health require the efficient and rapid translation of scientific discoveries into effective clinical treatments; this process, in turn, depends on observational data gathered from patients, communities, and public health research that can be used to guide basic scientific investigation. Such bidirectional translational science, however, faces unprecedented challenges due to the rapid pace of scientific and technological development, as well as the difficulties of negotiating increasingly complex regulatory and commercial environments that overlap the research domain.
Further, numerous barriers to translational science have emerged among the nation's academic research centers, including basic structural and cultural impediments to innovation and collaboration, shortages of trained investigators, and inadequate funding.
To address these serious and systemic problems, in 2006 the National Institutes of Health created the Clinical and Translational Science Awards (CTSA) program, which aims to catalyze the transformation of biomedical research at a national level, speeding the discovery and development of therapies, fostering collaboration, engaging communities, and training succeeding generations of clinical and translational researchers. The authors report in detail on the planning process, begun in 2008, that was used to engage stakeholders and to identify, refine, and ultimately implement the CTSA program's overarching strategic goals. They also discuss the implications and likely impact of this strategic planning process as it is applied among the nation's academic health centers. Acad Med. 2010; 85:463-469. Advancesinhumanhealthare dependent on the translation of emerging discoveries in molecular genetics, cellular biology, stem cell research, and other basic biomedical disciplines into clinically important applications, and on the effective societal deployment of proven applications to clinical practice. Translation of discoveries is a bidirectional process: Development of innovative strategies for the prevention, diagnosis, and treatment of human diseases requires that observations from patient-oriented, community-based, and public health research inform experiments in basic science laboratories. However, the conduct of bidirectional translational research is becoming more challenging because of the increasing complexities of both the basic and clinical sciences and the regulatory requirements for study conduct and marketing approval. In addition, a myriad of barriers to translational research have arisen, including the structural organization of traditional academic health centers, academic cultural impediments to collaboration, a shortage of translational investigators, the absence of mechanisms to facilitate translational research, and inadequate financial support. 1 The National Institutes of Health (NIH) catalyzed an effort to overcome these barriers on a national level in 2006 by creating the Clinical and Translational Science Awards (CTSA) program, which aims to develop and support the new discipline of "clinical and translational science." [2] [3] [4] During the third year of the program, the National CTSA Consortium embarked on the development and implementation of a comprehensive strategic plan focused on an agenda that is best addressed in a national unified manner through the consortium rather than at the local level at individual CTSA sites. In this article, we report the process and methods that were used, beginning in 2008, to develop the National CTSA Consortium's strategic plan, which will serve as the roadmap for the reengineering of the national translational research enterprise. of the expansion of the program from 24 to 38 sites during year 3 of the CTSA program. These program dynamics required that the strategic planning process employ a stepwise approach. By necessity, this approach had to be designed by existing CTSA sites, but it needed to include input from new sites that had not yet begun to implement their proposed transformative programs and did not have a comprehensive understanding about the organization and operations of the National CTSA Consortium.
In April 2008, Stage 1 of the planning process began with the identification and prioritization of strategic goals by the principal investigators (PIs) from the first 24 CTSA sites and key NIH representatives. This approach was chosen because the PIs were responsible for leading the transformation of the research enterprise at their own institutions and therefore were positioned to determine how coordinated National CTSA Consortium activities could supplement and leverage local efforts to transform the national research enterprise. The PIs agreed on four fundamental principles to guide this process:
• Consortium goals should focus on areas that could not be addressed by individual sites alone or by regional CTSA consortia.
• Education, training, and career development for clinical and translational scientists should serve as a cornerstone of the CTSA program.
• The consortium should identify process issues that are common barriers to research at CTSA sites and develop "best practices" to facilitate the conduct of clinical and translational research across the United States.
• The CTSA should serve as a federated network to conduct multisite clinical and translational research studies to optimize the efficiency of core facilities, to develop research tools, and to engage common stakeholders (e.g., lay community, industry).
Based on these fundamental principles, an iterative survey of the initial 24 PIs was conducted to identify and prioritize eight strategic goals. Further discussion among the PIs refined these goals and identified four additional goals (see List 1). • National resource inventory. Goal: To create a national searchable and interactive inventory of resources for clinical and translational research, including an inventory of technologies and services. Nested in this goal is the creation of a national biobank (i.e., systematic and accessible collection of biospecimens for common access and use).
• Clinical trial "network of networks." Goal: To develop a proof-of-principle approach through several examples of inter-CTSA site networks for the conduct of clinical trials. These examples will serve as the foundation for the National CTSA Consortium "network of networks," with each network focusing on specific diseases or conditions, and with the networks being linked by common data systems and informatics tools.
• Data-sharing network. Goal: To develop a national system of electronic data management and data sharing complemented by information technology tools. Key features of this goal include development of a common, searchable Web site for data storage and sharing, development of a common informatics infrastructure, and development of consortium-wide data-sharing policies.
• National phenotyping system. Goal: To develop a national phenotyping system, which requires establishment of phenotyping standards, informatics solutions, and data broker and access mechanisms.
• National model for community engagement. Goal: To develop effective national models for community engagement. Models should consider community-based participatory research, identification of health disparities, public input in the delineation of unmet medical needs, sharing of best practices, interfaces with practicing community physicians, increasing public trust, public education, identification of creative financial sources for community-based research, and leveraging ongoing efforts of NIH and other federal agencies.
• Social networking initiative. Goal: To develop a consortium-wide social networking initiative that facilitates "matchmaking" among scientists, trainees, and mentors. This initiative requires an informatics solution and its development timelines.
• Catalyze improved health through research. Goal: To support regional and national health care reform. This goal requires the development of guidance for research initiatives, collection of evidence to support health policies, public policy engagement, and a focus on effectiveness of research as it deals with health care.
Engagement of stakeholders
Stage 3 of the strategic planning process was designed to engage all stakeholders in the National CTSA Consortium in the streamlining and consolidation of the nine strategic goals, to identify organizational improvements that are required to align consortium and sitespecific activities with the strategic goals, and to begin to develop a comprehensive implementation plan. To seek broad input, the CTSA Steering Committee convened a consortium-wide meeting in October 2008 that included 112 CTSA PIs, chairs of consortium-wide key function committees (e.g., Informatics, The planning meeting began with a single group session that resulted in modification of and agreement on the final CTSA mission statement: "To improve human health by transforming the research and training environment, thereby enhancing the quality and efficiency of clinical and translational research." A modified Hoshin facilitation process 5 was then used to refine, delineate, and prioritize the nine previously identified strategic goals. The Hoshin process is a well-established strategic planning technique that is especially effective in large, disparate groups. To maximize the sharing of ideas through active group participation, meeting participants were divided into nine subgroups based on the previously identified strategic goals. Each group was led by two trained facilitators who implemented steps of a modified Hoshin process:
1. Mission creation-A five-year mission statement was created for each strategic goal.
2. Idea generation-Parallel ideation, idea clustering, and priority assignment were performed to identify critical implementation steps, their timelines, and the degree to which progress has been achieved thus far.
During this process, the strategic goals were further refined. Although all nine goals were deemed important to the CTSA mission, four main goals were constructed to illustrate the critical strategy of the National CTSA Consortium. The final four CTSA strategic goals, their subgoals, and their mission statements are described below.
Strategic Goal 1-Enhancing the national capability for clinical and translational research
This goal has three subgoals:
• CQI clinical research management system. To establish innovative, dynamic and transparent systems that will promote efficiency, quality, and safety in the conduct and life cycle of clinical and translational research within individual CTSA institutions and across the National CTSA Consortium in five years.
• Enhancement of national clinical study capability. To create links and common processes across CTSAs to amplify clinical study implementation and impact.
• National phenotyping. To develop appropriate standards and methods for phenotyping health and disease to facilitate clinical and translational research.
Strategic Goal 2-Enhancing the training and career development of clinical and translational scientists
This goal is to develop a national coordinated approach to recruit, educate, train, and promote the development of investigators across the evolving spectrum of clinical and translational research.
Strategic Goal 3-Enhancing consortium-wide collaborations
• National resource inventory. To catalog existing specialized resources throughout the CTSA that will be available to all investigators, and to identify areas where new resources are needed to accelerate clinical and translational research and to improve human health.
• Data-sharing network. To create datasharing mechanisms to facilitate innovation and collaborative research across the National CTSA Consortium.
• Social networking initiative. To build infrastructure to connect people and to promote and support collaborative multidisciplinary clinical and translational research.
Strategic Goal 4 -Enhancing the health of our communities and the nation
This goal has two subgoals:
• National model for community engagement. To identify and develop effective partnerships between academic researchers and community stakeholders that allow for participation, discovery, application, and dissemination of science that improves the public's health and reduces health disparities.
• Inform public health policy through research. To strengthen the scientific foundation of public policy and, consequently, to improve public health.
The Strategic Plan's Implementation
Consortium agreement on the four strategic goals provided a framework for the realignment of existing consortiumwide initiatives and the development of new initiatives that focus on achievement of the CTSA mission. Before embarking on the strategic planning process, the 9. Develop a conflict-of-interest policy that would be adopted as a "best practice" by all consortium sites.
10. Develop a social networking initiative to link scientists across the consortium.
11. Support regional and national health care reform.
12. Develop a coordinated national comparative animal model core and tissue biorepository.
* These goals were developed by an iterative survey of, and subsequent discussion among, the first 24 CTSA principal investigators.
CTSA program formed 15 committees, each of which focused on a CTSA key function (e.g., informatics; study design, biostatistics, and clinical research ethics; child health) and included representatives from each CTSA site and the NIH (see List 2) . In turn, these committees developed 83 task forces to focus on specific topics. Overall, this structure included more than 2,000 individuals. During the first two years of the CTSA program, these "key function committees" and their task forces identified topics and projects that they deemed would benefit from inter-CTSA collaboration and began to develop plans to focus on these projects. The committees essentially functioned independently from, and were not charged by, the CTSA PIs. Although this organizational structure resulted in productive committees of content area experts that made substantial progress in specific topic areas, it also led to an uncoordinated and largely underfunded effort that was dislocated from the CTSA PI Steering Committee's process of setting priorities for the consortium.
After the National CTSA Consortium identified its four strategic goals, it became apparent that mapping of the key function committees and subsequent coordination of their effort was the critical first step in the implementation of the consortium's strategic plan. To achieve the consortium's goals, four "strategic goal committees" were created. These strategic goal committees, each of which consists of a minimum of three CTSA PIs, three CTSA administrators, and one member of the NIH staff, have been charged by the CTSA PI Steering Committee to develop and implement specific plans to achieve the consortium's strategic goals. These plans require the identification of relevant expertise in, coordination among, and charging of the 15 key function committees. They may also involve the development of additional multidisciplinary task forces that include members drawn from different key function committees. For example, the social networking subgoal may require the development of a task force of domain experts drawn from the informatics, communications, education and career development, evaluation, and CTSA administrators key function committees. It is anticipated that this process will require systematic evaluation, reorganization, and likely absorption of key function committees into those designed to address the CTSA strategic goals. Consortium-wide resources will be focused on the four key goals to insure that the National CTSA Consortium meets its objectives and milestones.
In addition to managing the transition of the key function committees to work in support of the prioritized aspects of the strategic plan, the strategic goal committees are evaluating implementation steps identified during the Hoshin planning process. These tactical steps were provided to the strategic goal committees to guide the development and stratification of immediate and longer-range execution steps. As an example, List 3 illustrates specific implementation steps that were identified for the goal, "Enhancing the Training and Career Development of Clinical and Translational Scientists." Each strategic goal committee is using this type of information in the development of their implementation plans. This ongoing implementation process includes the identification of the scope of their strategic goal and prioritization of their subgoals, identification of which key function committees should be engaged, coordinated, and/or reorganized to achieve their goal, development of charges to relevant committees, and design of communications strategies to inform the National CTSA Consortium about their progress.
After the four committees initiated their plans to address the National CTSA Consortium's strategic goals, it became evident that the strategic plan did not fully address the inherent challenges of T1 translational research (i.e., the continuum of translational research in which laboratory-based scientific advances are translated into mechanistic studies in humans in pursuit of applications relevant to the improvement of human health). For example, T1 trainees are required to have a more substantial exposure to basic science compared with other clinical and translational scientists, and T1 research requires the integration of basic technologies (e.g., genomics, proteomics, metabolomics, computational biology) with clinical and molecular data. Accordingly, the consortium adopted a T1 translational research goal as its fifth strategic goal to (1) develop education and training requirements for T1 investigators, (2) encourage collaborative demonstration projects that will develop infrastructure for proof-of-concept studies in humans across different CTSA sites, and (3) develop efficient, effective, and consistent models of technology transfer.
Implications of the CTSA Strategic Plan
The achieved by leveraging the collaboration among these 46 (and, eventually, 60) institutions and the NIH as a National CTSA Consortium.
The CTSA planning process is unprecedented in both its projected inclusion of 60 major academic health centers and the NIH, and in its scope. The resulting CTSA strategic plan has five main goals: enhancement of (1) the national capability for clinical and translational research, (2) the training and career development of clinical and translational scientists, (3) consortiumwide institutional and scientific collaborations, (4) the health of our communities and the nation through the conduct of clinical and translational research, and (5) T1 translational research. This plan, which has been embraced by each of the 46 CTSA institutions and the NIH, serves as the roadmap to harness the creative transformations at CTSA institutions across the country for the purpose of reengineering the national clinical and translational research enterprise. Implementation of this plan will result in the development of a transinstitutional mechanism to facilitate research and health advances that would not otherwise be possible. The NIH's commitment to the CTSA strategic plan is demonstrated (1) by its funding commitment as part of the American Recovery and Reinvestment Act of 2009 to support several CTSA administrative supplements that specifically focus on the development of methods to implement the National CTSA Consortium's plans to achieve its five strategic goals and (2) by two large-scale grants to enable the national networking of scientists and resource discovery.
During year 4 (2009), consortium-wide initiatives were being developed in parallel to coordination of programs among small groups of CTSA institutions, including efforts that stem from regional collaborations. These selfassembled consortia provide opportunities for geographically centered interinstitutional interactions to leverage resources among CTSA sites. For example, these consortia can provide regional training opportunities, facilitate networking among trainees and scholars, develop novel methods for local dissemination of research findings, facilitate access to specialized resources, • Develop overarching framework for core training in clinical and translational science.
• Develop set of core competencies for trainees and graduates of clinical and translational research training.
• Define new skills that need to be developed.
• Develop standardized credentialing and certification criteria for clinical and translational investigators.
2. Continually improve trainee and program success.
• Establish common conflict-of-interest policy.
• Identify institutional homes for clinical and translational science within traditional academic structures.
• Develop process to "retrain" established researchers to focus on translational science.
• Develop and track short-and long-term career outcome measures relevant to human health.
• Measure self-efficacy.
• Measure effect of clinical and translational research training on clinical and translational research.
• Develop mechanism for CTSA sites to share programs, experiences, and outcomes.
• Agree to use evidence from evaluations to adapt training programs.
• Develop evidence-based understanding of what effectively promotes career development and success.
• Refine approaches to interdisciplinary training.
3. Ensure that institutions recognize that clinical and translational investigation is a valuable enterprise with unique metrics and criteria for success and promotion.
• Develop suggested national criteria for redefinition of academic promotion policies and requirements for clinical and translational scientists (policies must support team research).
• Identify benchmarks and timelines for promotion policies for clinical and translational scientists.
• Identify reward gaps in migrating a career between basic and clinical research.
• Develop program to educate deans and department chairs about the new field of clinical and translational science.
4.
Develop policies and mechanisms for support for investigators across the spectrum of their career development and the range of clinical and translational research.
• Support development of additional funding sources for clinical and translational research training programs.
• Develop consistent NIH K and CTSA KL2 award policies.
• Develop trans-NIH institute funding mechanisms for transition of trainees to independence.
• Ensure availability of adequate funding for trainees once trained.
• Create CTSA KL2 award that has flexibility and accountability, and leverages other available resources.
• Career development support: Develop recommended policies for NIH and other funders to provide predictable, clearly understandable, and competitive pathway to support careers of clinical and translational scientists.
• Engage in business development efforts to recruit sponsorships for training programs in order to address existing gaps in training and career development.
• Develop loan repayment programs.
• Develop new first award grants for clinical investigators.
5. Establish core curriculum that will address the needs of clinical and/or translational investigation.
• Develop common core curriculum for clinical and translational scientists, including training in public/private partnerships. • Develop agreements needed for institutions to share curricula and programs. and provide a framework to conduct multisite clinical trials within a geographic region. These regional groups plan to share best practices to guide the development of National CTSA Consortium-wide programs to achieve the five strategic goals.
Lessons Learned
The CTSA strategic planning process has demonstrated the effectiveness of a facilitated approach to consensus development among member institutions of the National CTSA Consortium. Within six months, 38 academic health centers collaboratively identified, refined, and implemented plans to achieve five overarching strategic goals for the CTSA program. Implementation of plans among the current 46 CTSA institutions will transform the national research enterprise to meet the NIH's vision for the CTSA program. The planning process has made it clear that the success of the CTSA program is dependent on the collaboration of institutions to jointly increase research efficiency, train and support a new cadre of scientists, and, ultimately, develop a new academic discipline of clinical and translational science.
